Suzanna Duncan, NP
Family · Gallipolis, OHNPI 1861852139
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,970 of the $45,483 with a category attached, or 92.3%. 35 manufacturers reported payments, led by Insulet Corporation at 57.0% of the total. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $163.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$26K
- Tandem Diabetes Care, Inc.$17K
- Dexcom, Inc.$719
- Novo Nordisk$293
- AstraZeneca$229
- AbbVie$196
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$41,97092%
- Food & beverage$3,5138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 62 | $25,931 |
| Tandem Diabetes Care, Inc. | 37 | $16,565 |
| Dexcom, Inc. | 42 | $719 |
| Novo Nordisk | 19 | $293 |
| AstraZeneca(2 entities) | 16 | $229 |
| AbbVie | 11 | $196 |
| Lilly USA, LLC | 12 | $188 |
| Boehringer Ingelheim | 9 | $152 |
| Sanofi-aventis U.S. LLC | 9 | $121 |
| Xeris Pharmaceuticals, Inc. | 6 | $112 |
| Biogen | 6 | $101 |
| Abbott | 5 | $97 |
| Bayer | 5 | $89 |
| Mannkind Corporation | 3 | $63 |
| Cequr Corporation | 2 | $63 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| BETA Bionics, Inc. | 6 | $48 |
| Adamas Pharmaceuticals, Inc. | 3 | $48 |
| Sanofi | 2 | $47 |
| Sequel Med Tech, LLC | 2 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Neurelis, Inc. | 1 | $35 |
| Chiesi USA, Inc. | 2 | $34 |
| Amgen(2 entities) | 2 | $31 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| Globus Medical | 1 | $21 |
| RGH Enterprises LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Recordati_rare_diseases_inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$25,600
- t:slim X2 Insulin Pump with Control-IQ$16,300
How this compares
$45,483 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 176 | $234,622 |
| Humalog Kwikpen U-200Insulin Lispro | 74 | $184,332 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $144,845 |
| OzempicSemaglutide | 116 | $142,000 |
| Tresiba Flextouch U-200Insulin Degludec | 84 | $130,184 |
| TrulicityDulaglutide | 57 | $80,012 |
| JardianceEmpagliflozin | 75 | $65,937 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $59,479 |
| FarxigaDapagliflozin Propanediol | 60 | $56,410 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 49 | $49,435 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $38,048 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 205 | $33,343 |
| Novolog FlexpenInsulin Aspart | 93 | $24,475 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $22,141 |
| NovologInsulin Aspart | 77 | $19,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $188 | $328,070276 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $293 | $174,821204 claims |
| Boehringer IngelheimJardiance | $152 | $65,93775 claims |
| AstraZenecaFarxiga | $229 | $56,41060 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $121 | $38,04836 claims |
| AbbVieSynthroid | $196 | $1,85926 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $1,258120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Gallipolis
- Kristin BierhupGallipolis$18K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.